Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy in high-risk localised prostate cancer

Expert Opinion on Investigational Drugs

Volumn 13, Issue 1, 2004, Pages 39-46

  Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Prostate cancer; Radical prostatectomy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; ESTRAMUSTINE; ETOPOSIDE; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE; WARFARIN;

ANTINEOPLASTIC ACTIVITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG POTENTIATION; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; LUNG EMBOLISM; MALE; NEUTROPENIA; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 1642514622     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.1.39     Document Type: Review

References (50)

1. EASTHAM JA, SCARDINO PT: Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology. Vogelzang NJ, Scardino PT, Shipley WU et al. (Eds), Lippincott Williams & Wilkins, Baltimore, MA, USA (2000 ):722-738.
2. GROSSFELD GD, CHANG JJ, BROERING JM et al.: Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J. Urol. (2001) 165(3):851-856.
3. EASTHAM JA, RIEDEL E, SCARDINO PT et al.: Variation of serum prostate specific antigen levels: an evaluation of year-to-year fluctuations in a well defined cohort of men. JAMA (2003) 289(20):2695-2700.
4. PARTIN AW, KATTAN MW, SUBONG EN et al.: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of locatised prostate cancer. A multi-institutional update. JAMA (1997) 277(18):1445-1451.
5. ROACH M 3rd, MARQUEZ C, YUO HS et al.: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localised prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. (1994) 28(1):33-37.
6. KATTAN MW, EASTHAM JA, STAPLETON AM, WHEELER TM, SCARDINO PT: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. (1998) 90(10):766-771.
7. GRAEFEN M, KARAKIEWICZ PI, CAGIANNOSI et al.: International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. (2002) 20(15):3206-3612.
8. BIANCO F Jr, KATTAN MW, SCARDINO PT, POWELL IJ, PONTES EJ, WOOD, DP Jr: Radical prostatectomy nomograms in black American men: accuracy and applicability. J. Urol. (2003) 170(1):73-76.
9. KATTAN MW, SHARIAT SF, ANDREWS B, ZHU K, MATSUMOTO K, SLAWIN K: The addition of interleukin-6 soluble receptor and transforming growth factor B-1 improves a pretreatment nomogram for predicting recurrence in patients with clinically localised prostate cancer. J. Clin. Oncol. (2003) 21(19):3573-3579.
10. GRAEFEN M, KARAKIEWICZ PI, CAGIANNOS I et al.: A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol. Oncol. (2002) 7(4):141-146.
11. KATTAN MW, ZELEFSKY MJ, KUPELIAN PA, SCARDINO PT, FUKS Z, LIEBEL SA: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. (2000) 18:3352-3359.
12. KATTAN MW, POTTERS L, BLASKO JC et al.: Pretreatment nomogram for predicting freedom from recurrence after permanent brachytherapy in prostate cancer. Urology (2000) 58:393-399.
13. KATTAN MW, REUTER V, MOTZER RJ, KATZ J, RUSSO P: A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. (2001) 166:63-67.
14. KATTAN MW, LEUNG DHY, BRENNAN MF: A postoperative nomogram for 12-year sarcoma-specific death. J. Clin. Oncol. (2002) 20:791-796.
15. KATTAN MW, KARPEH MS, MAZUMDAR M, BRENNAN MF: Postoperative nomogram for disease-specific survival following an R0 resection for gastric carcinoma. J. Clin. Oncol. (2003) 21(19):3647-3650.
16. KATTAN MW, SCARDINO PT: Prediction of progression: nomograms of clinical utility. Clin. Prostate Cancer (2002) 1:90-96.
17. SYED S, PETRYLAK DP, THOMPSON IM: Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches. Urol. Oncol.: Seminars and Original Investigations (2003) 21:235-243.
18. BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. (1997) 337(5):295-300.
19. ABBAS F, SCARDINO PT: Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol. Clin. North Am. (1996) 23:587-604.
20. VAN POPPEL H, AMEYE F, OYEN R et al.: Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy. Acta. Urol. Belg. (1992) 60:73-82.
21. RABBANI F, BASTAR A, FAIR WR: Neoadjuvant hormone therapy before radical prostatectomy: update on Phase II and III Memorial Sloan-Kettering Cancer Center trials. Mol. Urol. (1998) 2:151-157.
22. SCHELLHAMMER P, COCKETT A, BOCCON-GIBOD L et al.: Assessment of endpoints for clinical trials for localised prostate cancer. Urology (1997) 49:27-38.
23. GOLDENBERG SL, KLOTZ LH, SRIGLEY J et al.: Randomised, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localised prostate cancer. Canadian Urologic Oncology Group. J. Urol. (1996) 156:873-877.
24. SOLOWAY MS, PAREEK K, SHARIFI R et al.: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J. Urol. (2002) 167(1):112-116.
25. FAIR WR, RABBANI F, BASTAR A, BETANCOURT J: Neoadjuvant hormone therapy before radical prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center trials. Mol. Urol. (1999) 3(3):253-260.
26. WITJES WP, SCHULMAN CC, DEBRUYNE FM: Preliminary results of a prospective randomised study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology (1997) 49:65-69.
27. TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitaxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J. Clin. Oncol. (1996) 14(6):1756-1764.
28. KANTOFF PW, HALABI S, CONAWAY M et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. (1999) 17(8):2506-2513.
29. HARTLEY-ASP B, GUNNARSSON PO: Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J. Urol. (1982) 127(4):818-822.
30. STEARNS ME, WANG M, TEW KD, BINDER LI: Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J. Cell Biol. (1988) 107(6 Pt 2):2647-2656.
31. EKLOV S, NILSSON S, LARSON A, BJORK P, HARTLEY-ASP B: Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo. Prostate (1992) 20(1):43-50.
32. SPEICHER LA, LAING N, BARONE LR, ROBBINS JD, SEAMON KB, TEW KD: Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol. Pharmacol. (1994) 46(5):866-872.
33. HARTLEY-ASP B: Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate (1984) 5(1):93-100.
34. VAN POPPEL H, WERBROUCK PW, BAERT L: Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer. Acta. Urol. Belg. (1990) 58(4):89-95.
35. HUDES GR, NATHAN F, KHATER C et al.: Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. (1997) 15(9):3156-3163.
36. PETRYLAK DP, MACARTHUR R, O'CONNOR J et al.: Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone refractory prostate cancer. Semin. Oncol. (1999) 26(5 Suppl. 17):28-33.
37. SINABALDI VJ, CARDUCCI M, LAUFER M, EISENBERGER M: Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin. Oncol. (1999) 26(5 Suppl. 17):45-48.
38. PIENTA KJ, REDMAN B, HUSSAIN M et al.: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J. Clin. Oncol. (1994) 12(10):2005-2012.
39. KELLY WK, CURLEY T, SLOVIN S et al.: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol. (2001) 19(1):44-53.
40. PICUS J, SCHULTZ M: Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol. (1999) 26(5 Suppl. 17):14-18.
41. BEER TM, HOUGH KM, GARZOTTO M et al.: Treatment of androgen-independent prostate cancer with weekly high-dose calcitriol and docetaxel. 37th Annual Meeting of the American Society of Clinical Oncology (2001). (Abstract 2369).
42. BERRY W, GREGURICH M, DAKHIL S, HATHORN J, ASMAR L. Phase II randomised trial of weekly paclitaxel with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic prostate cancer. 37th Annual Meeting of the American Society of Clinical Oncology (2001). (Abstract 696).
43. SAVARESE DM, HALABI S, HARS V et al.: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.J. Clin. Oncol. (2001) 19(9):2509-2516.
44. CLARK PE, PEEREBOOM DM, DREICER R, LEVIN HS, CLARK SB, KLEIN EA: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology (2001) 57(2):281-285.
45. PETTAWAY CA, PISTERS LL, TRONCOSO P et al.: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J. Clin. Oncol. (2000) 18(5):1050-1057.
46. KONETY BR, EASTHAM J, SCARDINO PT et al.: Radical prostatectomy following neo-adjuvant chemo-hormonal therapy for high-risk or locally advanced prostate cancer: a Phase I/II study. J. Urol. (2004) (In press).
47. EASTHAM JA, KELLY WK, GROSSFELD GD, SMALL E: CALGB Trial 90203: randomised Phase III study of radical prostatectomy alone versus estramustine and docetaxel prior to radical prostatectomy for patients with high-risk localised disease. Urology (2004) (In press).
48. MESSING EM, MANOLA J, SAROSDY M, WILDING G, CRAWFORD ED,TRUMP D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med. (1999) 341(24):1781-1788.
49. STANFORD JL, FENG Z, HAMILTON AS et al.: Urinary and sexual function after radical prostatectomy for clinically localised prostate cancer: The Prostate Cancer Outcomes Study. JAMA (2000) 283:354-360.
50. MADALINSKA JB, ESSINK-BOT ML, DEKONING HJ, KIRKELS WJ, VAN DER MAAS PJ, SCHRODER FH: Health related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localised prostate cancer. J. Clin. Oncol. (2001) 19:1619-1628.